GI-6301
GI-6301 was a vaccine made from yeast carrying brachyury, the protein that chordomas depend on. Given with radiotherapy in a randomised trial it did not improve tumour responses.
Overview
GI-6301 was GlobeImmune's Tarmogen vaccine against brachyury, the notochord transcription factor whose expression defines chordoma and which also drives epithelial-to-mesenchymal transition in other cancers. Phase 1 testing at the National Cancer Institute showed brachyury-specific T-cell responses and some disease stabilisation in chordoma. A randomised, placebo-controlled phase 2 trial combined the vaccine with radiotherapy in locally advanced chordoma; it found no difference in objective response between the arms, although the vaccine was safe.
The chordoma page names it with adenoviral brachyury vaccines among the attempts to immunise against brachyury, alongside newer brachyury degraders and CDK7/9 inhibitors that lower its expression.
Saccharomyces cerevisiae engineered to express the transcription factor brachyury (TBXT), the driver of chordoma, is injected to raise brachyury-specific T cells; the yeast itself acts as the adjuvant.
1.GI-6301 slips into a pocket on its target.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"GI-6301" OR ABSTRACT:"GI-6301" OR TITLE:"Yeast-brachyury vaccine" OR ABSTRACT:"Yeast-brachyury vaccine") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GI-6301, not a curated reading list.